OSL2 Antibody

What is OSL2 Antibody and what are its primary research applications?

OSL2 has two relevant interpretations in research contexts:

• OSL2 as a breast cancer cohort: The OSL2 breast cancer cohort is a consecutive study collecting material from breast cancer patients with primary operable disease. In this context, antibodies are used to study DNA methylation patterns and distinguish patients according to ER (estrogen receptor) status. Research has shown that CpGs in Cluster 2 and in binding regions of ERα, FOXA1, and GATA3 had clear differences in methylation according to ER status, allowing separation of patients with ER positive versus ER-negative disease .

• Anti-OSR2 antibody: This refers to antibodies targeting Protein odd-skipped-related 2 (OSR2), such as the rabbit polyclonal antibody ab129897. This protein may be involved in the development of the mandibular molar tooth germ at the bud stage. Such antibodies are validated for Western Blot applications with human samples .

Primary research applications include analyzing protein expression patterns in cancer studies, investigating biomarkers for diagnosis and prognosis, and validating gene expression data at the protein level in developmental biology studies.

How do I select the appropriate antibody for my experimental design?

Selecting the right antibody requires careful consideration of multiple factors:

• Application and species validation

  • Ensure the antibody is validated for your specific application (WB, IHC, flow cytometry)

  • Check if it has been tested in your species of interest

  • Examine customer reviews for your specific application if the datasheet doesn't list it

• Antibody specificity

  • Look for antibodies validated with knock-out (KO) testing, which confirms specificity

  • A specific antibody should produce no signal in the KO sample but give a specific signal in wild-type samples

  • Example: Ki-67 antibody KO validation shows no expression in Ki67 knock-out HAP1 cells while showing clear expression in wild-type cells

• Immunogen details

  • Check if the immunogen sequence matches the region of the protein you're targeting

  • For cell surface proteins in flow cytometry, choose antibodies raised against the extracellular domain

• Sample processing compatibility

  • Some antibodies only recognize native protein conformations

  • Others only work with denatured/reduced proteins

  • For IHC, check if the antibody works with frozen sections or requires antigen retrieval in fixed tissue

• Host species considerations

  • Choose primary antibodies raised in a different species than your sample to avoid cross-reactivity

  • For mouse samples, use antibodies raised in rabbit, rat, or other non-mouse species

  • For non-model organisms, check sequence alignment between the immunogen and your protein (>85% suggests binding potential)

What controls should I include when validating antibody specificity?

Proper controls are essential for validating antibody specificity and ensuring reliable results:

• Positive controls

  • Use cell lines or tissues known to express the target protein

  • Consult BioGPS, The Human Protein Atlas, or published literature to identify appropriate positive controls

  • For phospho-specific antibodies, include samples with activated signaling pathways

• Negative controls

  • Cell populations not expressing the protein of interest

  • Knockout cell lines provide the strongest negative control

  • When a true negative isn't available, samples with low expression can serve as an alternative

• Isotype controls

  • Use an antibody of the same class as your primary antibody but with no specificity for your target

  • This helps assess background staining due to Fc receptor binding

  • Example: "Non-specific Control IgG, Clone X63" can serve as an isotype control

• Secondary antibody controls

  • For indirect detection, include samples treated only with labeled secondary antibody

  • This addresses non-specific binding of the secondary antibody

• Unstained controls

  • Particularly for flow cytometry, include unstained cells to assess autofluorescence

  • This helps identify false positive cells

For western blotting, a specific antibody should show a single band (or set of bands) of appropriate molecular mass. Extraneous bands indicate the antibody has additional targets and should raise concerns about specificity for IHC applications .

How do I optimize antibody dilution for my specific experimental setup?

Optimizing antibody dilution is crucial for achieving the best signal-to-noise ratio:

• Start with manufacturer recommendations

  • Review the datasheet for suggested dilution ranges

  • For example, anti-OSR2 antibody (ab129897) recommends a 1/500 dilution for Western blot

• Perform systematic titration

  • Create a serial dilution series of your primary antibody

  • For precise optimization, use a matrix approach testing both primary and secondary antibodies at different concentrations

  • For both primary and secondary antibodies, prepare antibody concentrations ranging from very dilute to concentrated

• Evaluate signal-to-noise ratio

  • Low antibody concentration: lower nonspecific signal but may decrease maximum signal

  • High concentrations: maximize positive signal but increase nonspecific background

  • Optimal dilution provides maximum difference between positive and negative signals

• Application-specific considerations

• Document optimal conditions

  • Once determined, record detailed information about optimal dilution, incubation time, and temperature

  • Note that the same antibody may require different dilutions for different applications or sample types

How can I implement knock-out validation to confirm antibody specificity?

Knock-out (KO) validation represents the gold standard for confirming antibody specificity:

• Principle and methodology

  • Test antibody on samples where the target gene has been deleted

  • A specific antibody should produce no signal in KO samples but give clear signal in wild-type samples

  • This serves as a true negative control that confirms binding only to the intended target

• Validation workflow

  • Obtain or generate appropriate KO samples:

    • CRISPR-Cas9 edited cell lines lacking target protein

    • KO cell lysates for western blotting

    • Tissue from transgenic knockout animals

  • Run wild-type and KO samples side by side under identical conditions

  • Include positive controls to ensure the assay is functioning properly

• Result interpretation

  • Complete absence of signal in KO samples indicates high specificity

  • Residual signal in KO samples suggests cross-reactivity with other proteins

  • Different signal patterns between applications may indicate context-dependent specificity

• Alternative approaches when KO is unavailable

  • RNA interference (RNAi) to knockdown target protein expression

  • Pre-adsorption of antibody with purified target protein

  • If extraneous bands are seen on Western blot, preadsorb the antiserum against tissue from knockout mice before using it for staining

• Documentation standards

  • Include images showing absence of signal in KO samples alongside wild-type controls

  • Document all experimental conditions thoroughly

  • Note any residual staining and provide interpretation

Example: In ICC/immunofluorescence validation for Ki67 antibody, wild-type cells show strong nuclear expression (green), while Ki67 knock-out HAP1 cells show no expression, confirming antibody specificity .

What are the best practices for using antibodies in multiple labeling experiments?

Multiple labeling experiments require careful planning to prevent cross-reactivity and ensure signal specificity:

• Experimental design principles

  • Optimize each primary/secondary antibody pair individually before combining

  • Use primary antibodies raised in different host species when possible

  • For fluorescent detection, select fluorophores with minimal spectral overlap

• Cross-reactivity prevention

  • CAUTION: Never dilute antibodies with normal serum or mix antibodies together, as this may form immune complexes and increase background

  • Use pre-adsorbed secondary antibodies that have been cleared of cross-reactive components

  • Blocking with 10% normal serum from the same host species as the secondary antibody reduces background

  • Ensure the blocking serum is NOT from the same host species as the primary antibody

• Pre-adsorption technique

  • Secondary antibodies can be pre-adsorbed by passing through a column containing immobilized serum proteins from potentially cross-reactive species

  • Only antibodies highly specific to the target IgG will flow through

  • Example: Anti-rabbit IgG light chain antibodies can be passed through a matrix containing sheep and bovine IgGs to eliminate cross-reactivity

• Sequential staining approach

  • When using primary antibodies from the same host species, implement sequential staining protocols

  • Complete one staining sequence with appropriate blocking before starting the next

  • The order of staining may need optimization when using both conjugated primary antibodies and secondary antibodies

• Key optimization tips

  • Select the brightest fluorophore for proteins with lowest expression

  • Use secondary antibodies from the same host species for all labels

  • Fragment antibodies (Fab, F(ab')₂) penetrate tissues more efficiently

  • For multiplexing validation, test each secondary antibody with all primary antibodies to confirm specificity

How do emerging SARS-CoV-2 variants impact antibody selection and cross-reactivity considerations?

The evolving nature of SARS-CoV-2 poses significant challenges for antibody-based detection and therapeutics:

• Challenge of viral evolution

  • SARS-CoV-2 continues to evolve, with variants showing immune evasion

  • Mutations in viral proteins can affect antibody binding epitopes

  • Variants such as Omicron have been reported to evade neutralization by some therapeutic monoclonal antibodies

• Strategic antibody targeting

  • Target conserved epitopes that are less likely to mutate

  • A proven approach involves using two antibodies in combination:

    • One antibody serves as an "anchor" by attaching to a conserved region of the virus

    • A second antibody inhibits the virus's ability to infect cells

  • This pairing strategy has shown effectiveness against the initial SARS-CoV-2 virus and all variants through Omicron in laboratory testing

• Cross-reactivity assessment

  • Test antibodies against spike proteins from multiple variants

  • Confirm neutralization activity with functional assays

  • Example: Antibody XBN-1 showed neutralization activity against both Delta (IC₅₀ of 7 ng/mL) and Omicron (IC₅₀ of 418 ng/mL)

• Predictive approaches for variant binding

  • Deep learning methods can predict antibody binding to new variants

  • The XBCR-net (cross-reactive B cell receptor network) has demonstrated ability to predict broadly reactive antibodies against SARS-CoV-2 variants

  • In testing against Omicron variants, XBCR-net correctly predicted 102/142 binders and 116/142 non-binders without prior knowledge of the variant

• Antibody engineering considerations

  • Antibodies derived from certain germline genes show broader cross-reactivity

  • Example: mAbs from the IGHV3-30, IGKV1-13 encoded cluster can bind to SARS-CoV, SARS-CoV-2, and Omicron variants

  • Targeting multiple regions increases resilience against viral mutations

What specific considerations apply to antibody-based flow cytometry compared to other applications?

Flow cytometry has unique requirements that differ from other antibody applications:

• Cell preparation fundamentals

  • For extracellular proteins, cells can often be used unfixed (live)

  • For intracellular targets, proper fixation and permeabilization are crucial

  • Cell viability should exceed 90% to avoid false positive staining from dead cells

  • Maintain cell concentration between 10⁵-10⁶ cells/tube to avoid clogging and obtain good resolution

• Critical antibody selection factors

  • Use flow cytometry-validated antibodies whenever possible

  • Antibodies successful in Western blot or IHC may fail in flow cytometry

  • Consider epitope location:

    • For surface proteins on live cells, use antibodies against extracellular domains

    • For intracellular targets, antibodies must access the interior after permeabilization

• Detection strategy optimization

  • Direct detection (conjugated primary antibodies):

    • Simplifies protocol and reduces background

    • Ideal for multicolor panels

    • Limited signal amplification requires abundant targets

  • Indirect detection (unconjugated primary + conjugated secondary):

    • Provides signal amplification for low-abundance proteins

    • Requires careful cross-reactivity control in multi-color experiments

• Essential control samples

  • Unstained cells: Assess autofluorescence

  • Single-color controls: Required for compensation in multicolor experiments

  • FMO (Fluorescence Minus One) controls: Critical for proper gating

  • Isotype controls: Evaluate non-specific binding through Fc receptors

  • Secondary antibody-only controls: Check background with indirect detection

• Protocol optimization tips

  • Keep cells on ice during all steps to prevent internalization of membrane antigens

  • Use PBS with 0.1% sodium azide to prevent protein internalization

  • If needed, frozen cells in PBS can be stored at -20°C for at least one week before analysis

• Troubleshooting common issues

  • For unexpected staining, verify secondary antibody specificity for species, class, and isotype

  • Ensure sufficient blocking to prevent non-specific binding

  • Include adequate washes between antibody applications

  • When multiplexing, optimize staining order to prevent secondary antibody cross-binding

How does sample processing affect epitope accessibility and what protocol modifications can improve antibody binding?

Sample processing significantly impacts epitope structure and antibody binding efficacy:

• Fixation effects on protein structure

  • Fixatives like formaldehyde create protein cross-links through methylene bridges

  • This alters protein conformation, potentially masking or exposing different epitopes

  • Some antibodies only recognize proteins in their native state, while others require denatured formats

• Application-specific processing requirements

  • Western blotting:

    • Many antibodies only recognize denatured/reduced proteins

    • Sample buffer composition and reducing agents affect epitope exposure

    • For fluorescent western blotting, omit Tween 20 from blocking buffer during initial blocking

  • Immunohistochemistry:

    • Some antibodies work only on unfixed frozen tissue

    • Formalin-fixed paraffin-embedded tissues often require antigen retrieval

    • The method of antigen retrieval (heat-induced vs. enzymatic) can significantly affect results

  • Flow cytometry:

    • For surface proteins, unfixed cells often yield best results

    • Different permeabilization agents (Triton X-100, saponin, methanol) expose different epitopes

    • Some epitopes are destroyed by certain permeabilization methods

• Buffer optimization strategies

  • PBS vs. TBS: Choose based on application and antibody requirements

  • Detergent concentration: 0.05% Tween 20 is typically sufficient to reduce background

  • Blocking agent selection: When BSA fails, try milk powder or synthetic blocking reagents

  • For fluorescent applications, use the product-specific primary antibody incubation buffer recommended by the manufacturer

• Antigen retrieval approaches

  • Heat-induced epitope retrieval (HIER):

    • Uses citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

    • Temperature and duration require optimization for each antibody

  • Enzymatic retrieval:

    • Uses proteases like proteinase K or trypsin

    • Can be gentler than HIER but may destroy some epitopes

• Protocol modification decision tree

  • For high background: Increase blocking, washing steps, or detergent concentration

  • For weak signals: Try different antigen retrieval methods, extend incubation times, or use signal amplification

  • For inconsistent results: Standardize fixation time, temperature, and buffer conditions

By understanding how sample processing affects epitope structure and accessibility, researchers can develop optimized protocols tailored to specific antibody-antigen interactions, maximizing signal while minimizing background or false negatives.